Pharma BD Deal Intelligence
Shionogi & Co., Ltd. granted Link Healthcare Singapore exclusive rights to develop and commercialize cefiderocol in Singapore and Malaysia. Cefiderocol is a first-in-class siderophore cephalosporin for serious Gram-negative bacterial infections that may be resistant to other antibiotics. The agreement extends an existing Shionogi relationship with the Link/Clinigen group, which received cefiderocol rights for Australia and New Zealand under a March 2025 agreement. Financial terms were not disclosed.
← Browse all deals · How we score deals
More: 2026 deals